Diabetology International最新文献_第3页

mTORC1 signaling and diabetic kidney disease. mTORC1 信号传导与糖尿病肾病。

IF 1.3

Diabetology International Pub Date : 2024-06-20 eCollection Date: 2024-10-01 DOI: 10.1007/s13340-024-00738-1

Vinamra Swaroop, Eden Ozkan, Lydia Herrmann, Aaron Thurman, Olivia Kopasz-Gemmen, Abhiram Kunamneni, Ken Inoki

{"title":"mTORC1 signaling and diabetic kidney disease.","authors":"Vinamra Swaroop, Eden Ozkan, Lydia Herrmann, Aaron Thurman, Olivia Kopasz-Gemmen, Abhiram Kunamneni, Ken Inoki","doi":"10.1007/s13340-024-00738-1","DOIUrl":"10.1007/s13340-024-00738-1","url":null,"abstract":"Diabetic kidney disease (DKD) represents the most lethal complication in both type 1 and type 2 diabetes. The disease progresses without obvious symptoms and is often refractory when apparent symptoms have emerged. Although the molecular mechanisms underlying the onset/progression of DKD have been extensively studied, only a few effective therapies are currently available. Pathogenesis of DKD involves multifaced events caused by diabetes, which include alterations of metabolisms, signals, and hemodynamics. While the considerable efficacy of sodium/glucose cotransporter-2 (SGLT2) inhibitors or angiotensin II receptor blockers (ARBs) for DKD has been recognized, the ever-increasing number of patients with diabetes and DKD warrants additional practical therapeutic approaches that prevent DKD from diabetes. One plausible but promising target is the mechanistic target of the rapamycin complex 1 (mTORC1) signaling pathway, which senses cellular nutrients to control various anabolic and catabolic processes. This review introduces the current understanding of the mTOR signaling pathway and its roles in the development of DKD and other chronic kidney diseases (CKDs), and discusses potential therapeutic approaches targeting this pathway for the future treatment of DKD.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 4","pages":"707-718"},"PeriodicalIF":1.3,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11512951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in glucagon research ~ 100th anniversary: invitation to the new 'glucagon-ology'. 胰高血糖素研究进展 ~ 100 周年：新 "胰高血糖素学 "邀请函。

IF 1.3

Diabetology International Pub Date : 2024-05-31 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00728-3

Dan Kawamori

引用次数: 0

Case of new-onset fulminant type 1 diabetes mellitus accompanied by autoimmune thyroid disease after SARS-CoV-2 infection. 感染SARS-CoV-2后新发暴发性1型糖尿病并伴有自身免疫性甲状腺疾病的病例。

IF 1.3

Diabetology International Pub Date : 2024-05-30 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00729-2

Keisuke Murakawa, Hiroaki Aasi, Kanako Sato, Saori Yoshioka, Hiroyuki Sho, Ryoko Inui, Motohiro Kosugi, Yoji Hazama, Tetsuyuki Yasuda

{"title":"Case of new-onset fulminant type 1 diabetes mellitus accompanied by autoimmune thyroid disease after SARS-CoV-2 infection.","authors":"Keisuke Murakawa, Hiroaki Aasi, Kanako Sato, Saori Yoshioka, Hiroyuki Sho, Ryoko Inui, Motohiro Kosugi, Yoji Hazama, Tetsuyuki Yasuda","doi":"10.1007/s13340-024-00729-2","DOIUrl":"10.1007/s13340-024-00729-2","url":null,"abstract":"There is growing evidence suggesting an association between severe acute respiratory coronavirus syndrome coronavirus 2 (SARS-CoV-2) infection and various extrapulmonary diseases since the advent of coronavirus disease 2019 (COVID-19) pandemic. However, case reports of fulminant type 1 diabetes mellitus (FT1D) following SARS-CoV-2 infection are limited. We encountered a 44-year-old Japanese woman who developed FT1D accompanied by subclinical thyrotoxicosis caused by autoimmune thyroid disease (AITD) approximately one week after SARS-CoV-2 infection. The patient developed fever and flu-like symptom 4 days before transportation and tested positive then for the SARS-CoV-2 antigen self-test. She subsequently developed sudden thirst, polyuria, and fatigue of 1 day duration and was urgently brought to our emergency room. Laboratory findings indicated diabetic ketoacidosis (DKA) without marked elevation of serum glycated hemoglobin (HbA1c) levels (glucose, 930 mg/dL; HbA1c, 7.4%). Her insulin secretory capacity was almost completely depleted, and islet-specific autoantibodies were negative. Endocrine examinations revealed subclinical thyrotoxicosis, which was positive for thyroid stimulation hormone receptor antibodies. Based on these results, the patient was diagnosed with FT1D accompanied by AITD and immediately started on intensive insulin therapy with a basal-bolus subcutaneous insulin regimen. Human leukocyte antigen analysis revealed haplotypes, indicating susceptibility to both FT1D and AITD. Further studies are required to elucidate the causal relationship between SARS-CoV-2 infection, FT1D, and AITD. However, clinicians must be vigilant about possible development of FT1D and AITD to enable accurate diagnosis and treatment of patients with DKA during the COVID-19 pandemic.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"621-626"},"PeriodicalIF":1.3,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus. 日本 2 型糖尿病患者从二肽基肽酶-4 抑制剂转为口服塞马鲁肽的疗效和安全性。

IF 1.3

Diabetology International Pub Date : 2024-05-30 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00734-5

Chihiro Yoneda, Junji Kobayashi, Nobuichi Kuribayashi

{"title":"Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.","authors":"Chihiro Yoneda, Junji Kobayashi, Nobuichi Kuribayashi","doi":"10.1007/s13340-024-00734-5","DOIUrl":"10.1007/s13340-024-00734-5","url":null,"abstract":"Background: Dipeptidyl peptidase-4 inhibitors (DPP-4is) are the most widely used oral hypoglycemic drugs in Japan. However, once-daily oral semaglutide has been reported to reduce glycated hemoglobin (HbA1c) and body weight (BW) without causing significant hypoglycemia. Here, we aimed to evaluate the efficacy and safety of switching from a DPP-4i to oral semaglutide in Japanese patients with type 2 diabetes (T2D).Methods: We performed a single-center retrospective study of the changes in HbA1c and BW in 68 patients with T2D who were switched from a DPP-4i and took oral semaglutide for ≥ 6 months, without changes in any other oral hypoglycemic agent.Results: Mean HbA1c decreased from 7.8 to 7.0% (p < 0.001) and BW decreased from 74.2 to 71.2 kg (p < 0.001) over 6 months. The decrease in HbA1c was more pronounced in participants with high baseline HbA1c (r = - 0.542, p < 0.001). There was also a trend (r = 0.236, p = 0.052) toward a decrease in BW in individuals with shorter disease duration. There were reductions in either HbA1c or BW in 65 participants (95.6%). In addition, the larger the decrease in HbA1c was, the greater was the decrease in BW (r = 0.480, p < 0.001). Eighteen participants (20.1%) discontinued the drug within 6 months, of whom 10 (11.6% of the total) did so because of suspected adverse effects and the discontinuation rate was the highest in older, non-obese patients.Conclusions: Switching from a DPP-4i to oral semaglutide may be useful for Japanese patients with T2D who have inadequate glycemic or BW control. However, its utility may be limited by gastrointestinal adverse effects in certain patients.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"569-576"},"PeriodicalIF":1.3,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe periodontal disease in Japanese patients with high HbA1c levels: a cross-sectional study. HbA1c 水平较高的日本患者的严重牙周病：一项横断面研究。

IF 1.3

Diabetology International Pub Date : 2024-05-28 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00732-7

Noboru Kurinami, Kenji Ashida, Seigo Sugiyama, Yoko Morito, Akira Yoshida, Kunio Hieshima, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Hideaki Jinnouchi, Masatoshi Nomura

{"title":"Severe periodontal disease in Japanese patients with high HbA1c levels: a cross-sectional study.","authors":"Noboru Kurinami, Kenji Ashida, Seigo Sugiyama, Yoko Morito, Akira Yoshida, Kunio Hieshima, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Hideaki Jinnouchi, Masatoshi Nomura","doi":"10.1007/s13340-024-00732-7","DOIUrl":"10.1007/s13340-024-00732-7","url":null,"abstract":"Objective: This study aimed to investigate the relationship between plasma glucose profiles and periodontal disease (PD) severity in men and women.Methods: We conducted a cross-sectional cohort study, enrolling all eligible patients with type 2 diabetes mellitus (T2DM) who regularly visited the outpatient department.Results: Patients were divided into severe and non-severe PD groups. The severe PD group showed a male predominance and significantly higher hemoglobin A1c (HbA1c) levels than the non-severe PD group. The optimal HbA1c cutoff value on the receiver operating characteristic curve for predicting severe PD was 7.3% [56 mmol/mol] (sensitivity, 52%; specificity, 73%; P = 0.01). Multivariate logistic regression revealed that male sex (odds ratio [OR], 2.75; 95% confidence interval [CI], 1.19-6.34; P = 0.01) and higher HbA1c levels (OR, 3.09; 95% CI, 1.42-6.70; P < 0 .01) were independently and significantly associated with the presence of severe PD. The prevalence rates of severe PD in patients with HbA1c levels < 7.3% [56 mmol/mol] and HbA1c levels ≥ 7.3% [56 mmol/mol] were 17.4% and 53.3% in women, and 50.0% and 66.7% in men, respectively.Conclusions: Men with T2DM had a high risk of severe PD independent of HbA1c levels. Plasma glucose management may be crucial for maintaining periodontal health in T2DM patients, particularly in women.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"562-568"},"PeriodicalIF":1.3,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovations and applications of ketone body monitoring in diabetes care. 酮体监测在糖尿病护理中的创新和应用。

IF 1.3

Diabetology International Pub Date : 2024-05-28 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00735-4

Naoki Sakane

{"title":"Innovations and applications of ketone body monitoring in diabetes care.","authors":"Naoki Sakane","doi":"10.1007/s13340-024-00735-4","DOIUrl":"10.1007/s13340-024-00735-4","url":null,"abstract":"Ketone bodies, comprising β-hydroxybutyric acid (BHB), acetoacetate (AcAc), and acetone, play a vital role as essential energy substrates. In individuals with diabetes, ketone bodies can be elevated under various conditions, including diabetic ketoacidosis, use of sodium-glucose transporter type 2 (SGLT2) inhibitors, and extreme carbohydrate restriction. There are three methods for measuring ketone bodies. Urine ketone analysis (AcAc) is a standard clinical test, whereas blood ketone testing (BHB+AcAc) is valuable in identifying or resolving diabetic ketoacidosis. Recently, technology for measuring breath acetone has been introduced, which provides an easy means of monitoring ketogenic diets in obese individuals. The basic breath alcohol detector also reacts with breath acetone. Therefore, it is important for professional drivers taking SGLT2 inhibitors to be cautious as workplace breath alcohol detectors may show false-positive results. Conversely, if a positive result is obtained, a detailed examination of ketosis is necessary. This review provides an overview of ketone body measurements in individuals with diabetes.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"370-378"},"PeriodicalIF":1.3,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudo-nephropathy and hyper-excretion of urinary C-peptide: an overlooked adverse effect of an angiotensin receptor-neprilysin inhibitor (ARNI). 假性肾病和尿 C 肽分泌过多：血管紧张素受体-肾素抑制剂 (ARNI) 被忽视的不良反应。

IF 1.3

Diabetology International Pub Date : 2024-05-28 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00730-9

Yoshito Itoh, Shigehito Suzuki, Ryohei Mineo, Sho Sasaki, Sachiko Tamba, Takuya Sugiyama, Koji Yamamoto

{"title":"Pseudo-nephropathy and hyper-excretion of urinary C-peptide: an overlooked adverse effect of an angiotensin receptor-neprilysin inhibitor (ARNI).","authors":"Yoshito Itoh, Shigehito Suzuki, Ryohei Mineo, Sho Sasaki, Sachiko Tamba, Takuya Sugiyama, Koji Yamamoto","doi":"10.1007/s13340-024-00730-9","DOIUrl":"10.1007/s13340-024-00730-9","url":null,"abstract":"Sacubitril/valsartan, which is a combined angiotensin receptor-neprilysin inhibitor (ARNI), is used for the treatment of chronic heart failure and hypertension. Substrates of neprilysin are numerous, and the systemic effects of an ARNI remain to be determined. Increased urinary C-peptide (UCPR) and urinary albumin (UAlb) excretion has been reported with the use of an ARNI, but the mechanism is still unknown. We report an 84-year-old man with type 2 diabetes and hypertension. His UAlb and UCPR excretion and (to a lesser degree) the estimated glomerular filtration rate were increased after ARNI administration. They returned to basal levels after discontinuing ARNI administration. There was little or no change in glycemic control. Therefore, increased glomerular permeability and filtration could partially explain how neprilysin inhibition led to an elevation in UCPR excretion, in addition to other mechanisms, such as impairment of the renal ability to degrade C-peptide. Physicians must be cautious when interpreting the insulin secretion capability by UCPR and nephropathy by UAlb in ARNI-treated patients with diabetes.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"616-620"},"PeriodicalIF":1.3,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Naming hypoglycemia: a narrative tool for young people with type 1 diabetes and their families. 为低血糖命名：1 型糖尿病青少年及其家庭的叙事工具。

IF 1.3

Diabetology International Pub Date : 2024-05-27 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00731-8

Francisco Sobral do Rosário, Marta Soares, Filipe Mesquita, João Filipe Raposo

{"title":"Naming hypoglycemia: a narrative tool for young people with type 1 diabetes and their families.","authors":"Francisco Sobral do Rosário, Marta Soares, Filipe Mesquita, João Filipe Raposo","doi":"10.1007/s13340-024-00731-8","DOIUrl":"10.1007/s13340-024-00731-8","url":null,"abstract":"Objective: Hypoglycemia constitutes a communication barrier between youth with type 1 diabetes, their family members and health professionals. A narrative tool may contribute to a more effective communication.Methods: Semi-structured interviews with six open-ended questions using narrative techniques collect and analyze (thematic and comparative analysis) different ways of \"naming\" the lived experience of hypoglycemia.Results: 103 participants, 40 with type 1 Diabetes aged 10-18 years (17 female), 63 relatives (40 female). Group 1 (G1), 10-14 years old (n = 21), Group 2 (G2), 15-18 years old (n = 19), Group 3 (G3) relatives, 30-59 years old. G3 was divided, G3.1: female (n = 42) and G3.2: male (n = 21).G1 and G2 presents greater attention to symptoms. G1 refers a greater need for help, G2 emphasizes autonomy. G2 and G3 describes better the medical protocol. G1 and G2 refer more topics such as \"discomfort\", \"frustration\", \"obligation\", \"difficulty in verbalizing\", G3 refers to \"gilt\", \"fear\" and \"responsibility\". G3.1 refer more \"symptoms\", \"responsibility\", \"fault\", \"incapacity\".Conclusions: A narrative tool enhances the singularity of a common experience, proving itself useful to adolescents, relatives, and healthcare professionals.Practice implications: In addition to gathering information that is usually acquired empirically, a narrative tool exposes knowledge gaps and may allow implementing intervention strategies.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"550-561"},"PeriodicalIF":1.3,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in basic research on glucagon and alpha cells. 胰高血糖素和α细胞基础研究的进展。

IF 1.3

Diabetology International Pub Date : 2024-02-26 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00696-8

Yoshitaka Hayashi

{"title":"Advances in basic research on glucagon and alpha cells.","authors":"Yoshitaka Hayashi","doi":"10.1007/s13340-024-00696-8","DOIUrl":"10.1007/s13340-024-00696-8","url":null,"abstract":"The regulation of plasma amino acid levels by glucagon in humans first attracted the attention of researchers in the 1980s. Recent basic research using animal models of glucagon deficiency suggested that a major physiological role of glucagon is the regulation of amino acid metabolism rather than to increase blood glucose levels. In this regard, novel feedback regulatory mechanisms that are mediated by glucagon and amino acids have recently been described between islet alpha cells and the liver. Increasingly, hyperglucagonemia in humans with diabetes and/or nonalcoholic fatty liver diseases is reported to likely be a compensatory response to hepatic glucagon resistance. Severe glucagon resistance due to a glucagon receptor mutation in humans causes hyperaminoacidemia and islet alpha cell expansion combined with pancreatic hypertrophy. Notably, a recent report showed that the restoration of glucagon resistance by liver transplantation resolved not only hyperglucagonemia, but also pancreatic hypertrophy and other metabolic disorders. The mechanisms that regulate islet cell proliferation by amino acids largely remain unelucidated. Clarification of such mechanisms will increase our understanding of the pathophysiology of diseases related to glucagon.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"348-352"},"PeriodicalIF":1.3,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acknowledgement to the Reviewers. 向审稿人致谢。

IF 2.2

Diabetology International Pub Date : 2024-01-12 eCollection Date: 2024-01-01 DOI: 10.1007/s13340-023-00690-6

引用次数: 0